Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ORMP, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Insulin | Type 2 Diabetes Mellitus | Phase 3 · NCT04606576 | Terminated |
| ORMD-0801 | Type 2 Diabetes Mellitus | Phase 3 · NCT06731075 | Not yet recruiting |
| ORMD 0801 | Brittle Type I Diabetes Mellitus | Phase 2 · NCT00867594 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ORMP holds $38M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 73.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ORMP files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORMP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →